

REVIEW

Direct suppression of autoreactive lymphocytes in the central nervous system via the CB₂ receptor

BN Dittel

BloodCenter of Wisconsin, Blood Research Institute, Milwaukee, WI, USA

The cannabinoid system is now recognized as a regulator of both the nervous and immune systems. Although marijuana has been used for centuries for the treatment of a variety of disorders, its therapeutic mechanisms are only now being understood. The best-studied plant cannabinoid, Δ^9 -tetrahydrocannabinol (THC), produced by *Cannabis sativa* and found in marijuana, has shown evidence of being immunosuppressive in both *in vivo* and *in vitro*. Since THC binds to at least two receptors that are differentially expressed by the immune and nervous systems, it has not been possible to clearly discriminate the biological effects it exerts in the two systems. In addition, endogenous cannabinoids have also been described that bind to both receptors and exert both neuronal and immune modulatory activity. The generation of mice deficient in specific cannabinoid receptors has facilitated studies to discriminate cannabinoid-specific functions. This review focuses on the function of the cannabinoid receptor 2 (CB₂), primarily expressed in the immune system, in regulating T cell effector functions associated with autoimmune inflammation in the central nervous system (CNS).

British Journal of Pharmacology (2008) **153**, 271–276; doi:10.1038/sj.bjp.0707493; published online 8 October 2007

Keywords: autoimmunity; cannabinoid receptor; experimental autoimmune encephalomyelitis; multiple sclerosis

Abbreviations: Anandamide/AEA, arachidonylethanolamide; 2-AG, 2-arachidonoylglycerol; CB, cannabinoid receptor; EAE, experimental autoimmune encephalomyelitis; IFN, interferon; MS, multiple sclerosis; MBP, myelin basic protein; h, T helper; THC, Δ^9 -tetrahydrocannabinol

Introduction

Diseases of the nervous system are diverse and result in ~9% of all human deaths (Bergen and Silberberg, 2002). The most prevalent immune-mediated disease of the CNS is multiple sclerosis (MS) (Sospedra and Martin, 2005). In the CNS of MS patients, inflammatory plaques form, which contain immune cells that are thought to drive both demyelination and neuronal dysfunction resulting in a variety of clinical symptoms (Sospedra and Martin, 2005). Although clinically very devastating, there are no highly successful treatments available for MS. Because the cannabinoid system has been shown to be anti-inflammatory and negatively regulate immune cell functions, there is interest in cannabinoid-based therapies for MS. The cannabinoid system can modulate/regulate both neuronal and immune functions; therefore, it is not clear whether cannabinoid-based therapies that demonstrate efficacy are due to effects on the immune or nervous system or both. There is yet much to be learnt about how the cannabinoid system interacts with and regulates the immune system in a CNS disease like MS.

In MS and its animal model experimental autoimmune encephalomyelitis (EAE), the pathogenic cell is thought to be a CD4 T cell that recognizes and mounts an immune response against 'self-antigens' in the myelin sheath (Sospedra and Martin, 2005). However, CD8 T cells have also been shown to be pathogenic in specific EAE models (Huseby *et al.*, 2001; Ji and Goverman, 2007; Johnson *et al.*, 2007). The autoimmune attack results in inflammatory lesions in the CNS composed of CD4 and CD8 T cells, B cells and macrophages, and is accompanied by demyelination and motor neuron defects (Sospedra and Martin, 2005). Recently, using the mouse model of MS, EAE, we have shown that the cannabinoid system directly regulates the CD4 self-reactive T cell modulating the severity of disease (Maresz *et al.*, 2007). These data will be discussed.

The endocannabinoid system

The cannabinoid system is evolutionally conserved and is present in invertebrates and vertebrates (Salzet *et al.*, 2000). One of the best-studied cannabinoids is Δ^9 -tetrahydrocannabinol (THC), the predominant active component of *Cannabis sativa* or marijuana. The marijuana plant has been exploited

Correspondence: Dr BN Dittel, BloodCenter of Wisconsin, Blood Research Institute, PO Box 2178, 8727 Watertown Plank Road, Milwaukee, WI 53201-2178, USA.

E-mail: bonnie.dittel@bcw.edu

Received 13 July 2007; revised 31 August 2007; accepted 3 September 2007; published online 8 October 2007

by humans since their early history and was used for centuries in Asian medicine to reduce the severity of pain, inflammation and asthma (Berdyshev, 2000). However, only recently have the mechanisms of the medicinal properties of THC begun to be understood. This understanding is largely due to the identification and cloning of two cannabinoid receptors. The CB₁ receptor is expressed primarily by neurons (Matsuda *et al.*, 1990), and at low levels in cells of the immune system (Kaminski *et al.*, 1992). The identification of the CB₂ receptor, which is expressed primarily by immune cells (Munro *et al.*, 1993; Galiègue *et al.*, 1995), provided a basis for the immunomodulatory properties of THC. The CB₂ receptor has recently been shown to be also expressed by some neurons in the brain stem (Van Sickle *et al.*, 2005). Identification of arachidonylethanolamide (anandamide, AEA) (Devane *et al.*, 1992) and 2-arachidonoylglycerol (2-AG) (Mechoulam *et al.*, 1995; Sugiura *et al.*, 1995), as two lipid ligands for the CB₁ and CB₂ receptors, initiated studies examining the role of 'endocannabinoids' in the maintenance of physiological homeostasis and the development of certain neuronal and immune system diseases. 2-AG is produced at nanomolar amounts in the brain and spinal cord (Baker *et al.*, 2001). Of the two major endocannabinoids, evidence points to 2-AG as the primary endocannabinoid agonist at the CB₂ receptor (Sugiura *et al.*, 2000a). Endocannabinoid levels are regulated by synthesis and degradation; AEA is metabolized intracellularly by fatty acid amide hydrolase (Schmid *et al.*, 1985) and 2-AG by monoglyceride lipase (Saario *et al.*, 2004). Both enzymes result in the production of arachidonic acid, the precursor to the immune-regulatory prostaglandins and other eicosanoids. Other endocannabinoids have been described, but their biological functions are not well understood (Saario *et al.*, 2004). In addition, a number of synthetic cannabinoid receptor agonists and antagonists have been developed, of which some have preferential binding to one of the two receptors. These synthetic cannabinoids have been used in many published studies.

Cannabinoid receptors are G-protein-coupled receptors that are linked to G_{i/o}-proteins (Berdyshev, 2000), and negatively regulate adenylate cyclase and the accumulation of intracellular cAMP (Schatz *et al.*, 1997). Intracellular cAMP regulates PKA activation, which in turn has a major role in gene regulation in immune cells. The prevailing hypothesis is that the cAMP-dependent signalling positively regulates the establishment of immune responses and that cannabinoid receptor signalling can antagonize early events associated with immune cell activation (Berdyshev, 2000). In other words, signalling through the CB₂ receptor is thought to negatively regulate immune cell function. This negative regulation could contribute to the development of disease processes or be exploited for the treatment of disease.

The endocannabinoid system and the immune system

Although first described in the nervous system, it is becoming increasingly clear that the endocannabinoid system plays an important role in modulating immune

function. Although underappreciated in the past, the linkage of the nervous and immune systems is becoming a well-established concept. When immunology meets the nervous system, this is termed 'neuroimmunology'. In neurological diseases with an immune component, it is difficult to discern when the immune system is regulating the nervous system and when the nervous system is regulating the immune system. Even when it is clear that one system is regulating the other, the mechanisms involved are extremely difficult to unravel. This is certainly the case with the endocannabinoid system, because its regulation is not on or off, but rather a tuning effect.

The endocannabinoid system has been speculated to modulate immune functions through the CB₂ receptor. The expression of the CB₂ receptor in haematopoietic cells has primarily been measured using reverse transcription (RT)-PCR methods, and it was reported that human haematopoietic cell populations differ in the level of CB₂ receptor expression and are ranked in the following order: B cells > natural killer cells > monocytes > polymorphonuclear neutrophils > CD8 T cells > CD4 T cells (Galiègue *et al.*, 1995). A similar CB₂ expression pattern was reported for mouse immune cells (Lee *et al.*, 2001).

The immune modulatory activities of the endocannabinoids are extensive and are thought to include inhibition of T-cell proliferation, decreased cytokine production by T cells, dysregulation of the T helper (h)1/Th2 cytokine balance, perturbation of immunoglobulin production, downregulation of CD8 cytotoxic T-cell activity and impairment of macrophage function (Klein *et al.*, 1991, 2004; Schatz *et al.*, 1993; Condie *et al.*, 1996; Berdyshev, 2000; Yuan *et al.*, 2002). Most of these studies have been performed *in vitro*. Some of these immunological defects are likely due to disruptions in T-cell interactions with antigen-presenting cells (Berdyshev, 2000). In addition to these *in vitro* effects, it has been shown that administration of high-dose THC in mice resulted in decreased resistance to *Listeria monocytogenes* or *Herpes simplex virus* (Morahan *et al.*, 1979). Although the list of possible immunological perturbations by the endocannabinoid system is extensive, regulation of any specific immune response that results in autoimmunity or protective immunity are not well studied or understood.

One caution regarding the interpretation of immunological *in vitro* experiments is that fetal calf serum contains high levels of AEA and other *N*-acylethanolamides (Berdyshev *et al.*, 2000). In addition, many natural and synthetic cannabinoids bind to both the CB₁ and CB₂ receptors, making it impossible to clearly assess the role of each receptor in the immune processes measured. The generation of CB₁ and CB₂ cannabinoid receptor knockout mice have facilitated studies examining the regulation of immune responses by the endocannabinoid system. In the study describing the CB₂^{-/-} mouse, the immune modulatory function of the CB₂ receptor on macrophages was confirmed by showing that THC failed to inhibit T-cell IL-2 production in the presence of CB₂^{-/-} macrophages (Buckley *et al.*, 2000). Thus, the CB₂^{-/-} mouse is an excellent model to study the role of the CB₂ receptor in immune responses.

Cannabinoids and MS

There is increasing evidence that a major physiological function of the endocannabinoid system is in the regulation of neuroinflammation. CNS inflammation occurs in a variety of clinical situations including Alzheimer's disease, ischaemia and traumatic brain injury (Walter and Stella, 2004). However, none of these are considered to be immune-mediated diseases. One of the best-studied immune-mediated diseases of the CNS is MS (Sospedra and Martin, 2005). MS is a human auto-immune disease of the CNS that results in focal areas of inflammation that contain immune cell infiltrates and areas of demyelination (Sospedra and Martin, 2005). The prevailing view is that MS is initiated by CD4 T cells of the Th1 subtype. These Th1 T cells are so characterized because they produce the proinflammatory cytokine interferon (IFN)- γ . Th1 cell production of IFN- γ and other proinflammatory cytokines, such as tumour necrosis factor- α and granulocyte-macrophage-colony stimulating factor are thought to drive the inflammatory process in MS. In MS, these Th1 cells have specificity to 'myelin' antigens expressed by oligodendrocytes. These 'self-antigens' include myelin basic protein (MBP), myelin oligodendrocyte protein and proteolipid protein.

Individuals with MS often undergo a dramatic life alteration. The symptoms of MS can be associated with any function of the CNS, since the immune cell-mediated inflammation can occur virtually in any area of the CNS, including the spinal cord. In addition, it is becoming clear that neuronal dysfunction and even neuronal loss are present even early in the MS disease course (Sospedra and Martin, 2005). One of the most prevalent symptoms of MS is the loss of motor function. This can occur to such an extent that individuals with MS have trouble walking and holding objects. Since MS most often strikes women between the ages of 20 and 40 years (Sospedra and Martin, 2005), life alterations often include a change in employment status and a reduced inability to care for children. Because there is no cure for MS and treatments are limited, much research needs to be done on the immunological mechanisms involved in the pathogenesis of MS.

Because of the psychotropic effects of CB₁ receptor signalling, one of the more controversial treatments for MS is the smoking of marijuana or the administration of THC or other components of *C. sativa*. Clinical studies have suggested beneficial effects of cannabinoids in MS symptoms of neuronal in nature including spasticity, pain, tremor and nocturia (Pertwee, 2002). However, a recent clinical trial examining the effect of THC on the control of spasticity concluded that no beneficial effect occurred (Zajicek *et al.*, 2003). Also, a more recent 2004 review of all clinical trials that did not include the Zajicek trial (Zajicek *et al.*, 2003), examining the use of cannabis in individuals with MS, concluded that the results were equivocal (Killestein *et al.*, 2004). Since these trials primarily examined neuronal effects, it is still unclear as to whether immune modulation by cannabinoids would be beneficial in MS.

EAE and cannabinoids

The best-studied animal model of MS is EAE in mice. EAE recapitulates much of the MS clinical disease, including the

presence of inflammatory lesions, demyelination and neuronal dysfunction/loss. As with MS, the inflammatory lesions primarily consist of T cells and macrophages. EAE can be induced by the immunization of susceptible mouse strains with myelin antigens emulsified in complete Freund's adjuvant in combination with the injection of *Bordetella pertussis* toxin. EAE induced by this active immunization protocol begin to exhibit clinical disease starting around day 14. The severity of clinical disease steadily increases over about a week, beginning as tail weakness and then progressing as an ascending paralysis. Depending on the strain of mouse used, the mice will exhibit a chronic disease course or undergo spontaneous recovery. Some mouse strains will also relapse. A second method of EAE induction is the adoptive transfer of activated myelin-specific T cells into sublethally irradiated hosts. In this adoptive transfer model, the mice exhibit signs of clinical EAE starting at day 7. The clinical progression and recovery is very similar to that observed with active induction.

Unlike with MS, treatment of EAE with cannabinoids revealed a clear therapeutic benefit (Walter and Stella, 2004). The general consensus from a number of studies is that administration of either plant derived (THC) or synthetic cannabinoids with selectivity for the CB₁ and/or CB₂ receptors reduced clinical signs of EAE, including spasticity and tremor and paralysis (Lyman *et al.*, 1989; Wirguin *et al.*, 1994; Achiron *et al.*, 2000; Baker *et al.*, 2001). In a chronic relapsing EAE model, the use of selective antagonists for the CB₁ and CB₂ receptors demonstrated a role for both receptors in controlling spasticity, with evidence for the CB₁ receptor being the main target (Baker *et al.*, 2000). Several studies have examined the effect of cannabinoid treatment using the Theiler's murine encephalomyelitis virus model of MS. In this model, mice are intracerebrally injected with the virus and the mice develop clinical signs, similar to EAE, about 30 days later. In these studies, synthetic cannabinoids were effective in decreasing clinical disease (Arévalo-Martín *et al.*, 2003; Croxford and Miller, 2003). Two additional studies showed that the administration of an inhibitor of the putative endocannabinoid transporter also reduced TMEV clinical disease (Mestre *et al.*, 2005; Ortega-Gutierrez *et al.*, 2005). Similarly, in a chronic relapsing model of EAE, spasticity was also ameliorated by a competitive endocannabinoid uptake inhibitor and by a selective inhibitor of fatty acid amide hydrolase (Baker *et al.*, 2001). Mechanisms that have been suggested for the suppression of EAE via the cannabinoid system include induction of encephalitogenic T-cell apoptosis and reduced migration of immune cells into the CNS (Ni *et al.*, 2004; Sánchez *et al.*, 2006). Thus these cumulative studies suggest that the cannabinoid system could be manipulated for the treatment of MS. However, since the above studies did not use endogenous cannabinoid receptor ligands, it is unclear how the 'endocannabinoid' system functions in regulating CNS inflammation.

CB₁ receptor in regulating EAE

One of the drawbacks in using either natural or synthetic cannabinoids to study the functions of the cannabinoid system is that they all exhibit some level of binding affinity

for both the CB₁ and CB₂ receptors. The same is true for the CB receptor antagonists. Thus, the strategy of administering cannabinoids to wild-type mice to modulate EAE does not allow a clear distinction between CB₁ and CB₂ receptor-mediated effects. Functional differentiation between the two receptors became possible upon the creation of knockout mice lacking either receptor. Mice deficient in the CB₁ receptor were susceptible to EAE induction; however, they did not recover from paralysis to the same extent as the wild-type controls and they exhibited greater neurodegeneration (Pryce *et al.*, 2003). These data provided further evidence that the CB₁ receptor regulated neuroinflammation associated with EAE. To distinguish between CB₁ receptor effects mediated by the immune versus nervous system, Dr D Baker and colleagues generated conditional knockout mice using lineage-specific promoters specific for T cells or neurons (Maresz *et al.*, 2007). Using THC to inhibit EAE, it was shown that mice which were completely deficient of the CB₁ receptor were refractory to its effects. Mice with a CB₁ receptor deficiency in T cells were responsive to THC inhibition of EAE; whereas, mice lacking neuronal CB₁ receptor were not. These cumulative data demonstrate that THC mediates its effects through the CB₁ receptor expressed by neurons and that T-cell CB₁ receptor expression is dispensable for the regulation of EAE.

CB₂ receptor in regulating T-cell effector function in the CNS

Using a similar knockout strategy, we investigated the role of the CB₂ receptor on both nervous and immune tissue in regulating EAE disease. This was accomplished by inducing EAE in CB₂ receptor-deficient mice (CB₂^{-/-}) (Buckley *et al.*, 2000). These experiments utilized CB₂^{-/-} mice bred onto the B10.PL background (H-2^u) and encephalitogenic T cells bearing a transgene with specificity for MBP in the context of I-A^u (Dittel *et al.*, 1999). When EAE was induced by the immunization with the Ac1-11 encephalitogenic peptide comprising the first 11 amino acids of MBP with the first residue acetylated, CB₂^{-/-} mice were shown to be more susceptible to disease induction than wild-type littermates (Maresz *et al.*, 2007). In addition, EAE disease in the CB₂^{-/-} mice was more severe, and the mice failed to exhibit recovery from clinical signs as observed in wild-type mice (Maresz *et al.*, 2007). When EAE was induced in CB₂^{-/-} mice by the adoptive transfer of wild-type encephalitogenic T cells no change in disease parameters was observed as compared to wild-type mice (Maresz *et al.*, 2007). In contrast, when EAE was induced in wild-type mice with CB₂ receptor-deficient encephalitogenic T cells, the mice exhibited disease that was statistically and significantly more severe, with a higher rate of mortality and complete lack of recovery, as compared to disease induced with wild-type T cells (Maresz *et al.*, 2007). These cumulative data indicate that the cannabinoid system, via the CB₂ receptor on the autoreactive T cells, regulates the extent of the immune response in the CNS. These data also indicate that CB₂ receptor expression by CNS tissue nor by endogenous immune cells is important for the regulation of CNS autoimmunity.

We explored further the mechanism of the CB₂ receptor regulation of EAE. We found that T cells deficient in the CB₂ receptor exhibited enhanced effector functions in the CNS during EAE. We found that CB₂^{-/-} T cells were more prevalent in the CNS during EAE indicative of their higher rates of proliferation and reduced level of apoptosis (Maresz *et al.*, 2007). Increased numbers of T cells is consistent with more severe clinical EAE disease. These T cells were also shown to be producing increased levels of the proinflammatory cytokines IFN- γ and macrophage-colony stimulating factor (Maresz *et al.*, 2007). No changes in these T-cell effector parameters were observed in the spleen, indicating that a CNS-specific regulation of T-cell effector function via the CB₂ receptor occurs during EAE, and by inference MS. The CB₂ receptor-specific regulation of T-cell proliferation and cytokine production was confirmed *in vitro* in the CB₂^{-/-} encephalitogenic T cells using the CB₂ receptor agonist JWH-133 (Huffman *et al.*, 1999).

Finally, we investigated the extent to which the cannabinoid system regulates T-cell effector function in the CNS. When we reduced the number of encephalitogenic T cells used to induce EAE from 1×10^6 to 0.5×10^6 cells, EAE was either prevented or was very mild following transfer of wild-type T cells. In contrast, 0.5×10^6 CB₂^{-/-} T cells was sufficient to induce disease in 100% of the mice, and resulted in a chronic disease course without signs of recovery (Maresz *et al.*, 2007). In B10.PL mice, 1×10^6 wild-type encephalitogenic T cells do not typically induce disease unless the recipient mice have been irradiated prior to the T-cell adoptive transfer. However, we found that the irradiation was dispensable when EAE was induced with CB₂^{-/-} T cells (Maresz *et al.*, 2007). This finding is particularly interesting since we have shown that irradiation reduces spinal cord 2-AG content (Maresz *et al.*, 2005), which would result in reduced CB₂ receptor activation and could be part of the mechanism by which irradiation enhances the induction of EAE. Similarly, the CB₂ receptor is coupled to G proteins of the α_1 subclass, so its signalling is *B. pertussis* toxin sensitive (Munro *et al.*, 1993). EAE induction by immunization is enhanced by the treatment of mice with *B. pertussis* toxin (Munoz *et al.*, 1984); thus, perhaps part of the mechanism of the toxin is to reduce CB₂ receptor signalling on T cells.

Concluding remarks

The mechanism by which central cannabinoid receptors modulate immune function is not definitively known, although it is likely to be the product of a number of interacting systems that result in the inhibition of the generation of effector Th1 cells that can enter the CNS to trigger disease. To examine the role of the CB₂ receptor in the regulation of CNS autoimmunity, we utilized CB₂ receptor knockout mice on the B10.PL background so that we could utilize the MBP-TCR tg mouse to specifically study the role of the CB₂ receptor on encephalitogenic T cells. Our primary finding is that the effector functions of autoreactive T cells are strongly repressed by the CNS microenvironment through the CB₂ receptor, without the need for exogenously

added cannabinoid agonists. These effects were CNS-specific, as similar alterations in T-cell effector function were not observed in the spleen. These data extend our previous report that encephalitogenic T cells in the CNS express the CB₂ receptor during EAE (Maresz *et al.*, 2005), and strongly suggest that the presence of CB₂ receptors on T cells exerts an immunosuppressive effect when the T cells have migrated into the CNS. We also found that CB₂ receptor expression by all body tissues, including the CNS, and haematopoietic cells other than the encephalitogenic T cells is not required for the receptor's immunosuppressive function. For the CB₁ receptor, expression by neurons, but not T cells, was required for its regulation (Maresz *et al.*, 2007).

Of interest is the CNS specificity of the cannabinoid-based regulation of EAE, as demonstrated by the observation that in contrast to the profound difference in the CNS, the proliferation, apoptosis and cytokine production of CB₂^{-/-} T cells in the spleen were not different from wild type. One likely explanation for this finding is that the spleen expresses lower concentrations of the endogenous agonist ligands for the CB₂ receptors than the CNS. Two arachidonate derivatives, anandamide and 2-AG are proposed to serve as endogenous activators of the CB₁ and CB₂ receptors (Klein, 2005). 2-AG has higher efficacy at the CB₂ receptor than anandamide (Sugiura *et al.*, 2004), and is present at higher concentrations than anandamide in the CNS (Patel *et al.*, 2005) and is likely more important physiologically. The amount of 2-AG in the rodent brain is estimated between 3 and 10 nmol g⁻¹ tissue while the content in spleen is 3- to 10-fold lower (Sugiura and Waku, 2000). These data suggest that CB₂-mediated inhibition would play a more important role in the regulation of T-cell function in the brain than in the spleen and are consistent with our finding that splenic T cells were unaffected by the lack of CB₂ receptors. Interestingly, total plasma levels of 2-AG are 0.012 nmol ml⁻¹ or 12 nM (Sugiura and Waku, 2000), which is significantly less than its estimated K_D for the CB₂ receptor (1 μM) (Shoemaker *et al.*, 2005) and suggests that the T-cell CB₂ receptor is not activated when the cells are circulating in the blood but become activated when the cells migrate into tissues with high 2-AG content, such as the CNS. It is our hypothesis that CB₂-mediated suppression of T-cell function is an important component of the mechanism by which the CNS is immune-protected.

These studies are theoretically in agreement with the suggestions of others that cannabinoid receptor agonists would be beneficial for the treatment of MS in humans (Pertwee, 2002). Alternative approaches would be to enhance CB₂ receptor-mediated immune-suppression by increasing endocannabinoid content in the brain (Ortega-Gutierrez *et al.*, 2005) or by upregulating CB₂ receptor expression on T cells. If cannabinoid-based strategies can reduce or control CNS inflammation this has the potential to retard the progression of MS.

Our cumulative data indicate that the CB₂ receptor plays a prominent role as an inhibitory receptor in activated encephalitogenic T cells. We suggest that T cells encounter CB₂ receptor ligand at high concentrations in the CNS microenvironment, which actively suppresses their function. Thus, we propose that an important function of the CNS

cannabinoid system is to maintain an anti-inflammatory microenvironment, so that entrance of activated T cells into the CNS generated during autoimmunity and infections does not lead to tissue damage.

Acknowledgements

We thank Drs Cecilia Hillard, Eugene Ponomarev, Katarzyna Maresz and Nancy Buckley without whom none of the studies discussed on the CB₂ receptor could have been performed; and Dr David Baker and colleagues for sharing their elegant studies on the CB₁ receptor. Bonnie Dittel was supported by NIH Grant R01 NS046662 and the BloodCenter Research Foundation.

Conflict of interest

The author states no conflict of interest.

References

- Achiron A, Miron S, Lavie V, Margalit R, Biegon A (2000). Dexamethasone (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. *J Neuroimmunol* **102**: 26–31.
- Arévalo-Martín A, Vela JM, Molina-Holgado E, Borrell J, Guaza C (2003). Therapeutic action of cannabinoids in a murine model of multiple sclerosis. *J Neurosci* **23**: 2511–2516.
- Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW *et al.* (2000). Cannabinoids control spasticity and tremor in a multiple sclerosis model. *Nature* **404**: 84–87.
- Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A *et al.* (2001). Endocannabinoids control spasticity in a multiple sclerosis model. *FASEB J* **15**: 300–302.
- Berdyshev EV (2000). Cannabinoid receptors and the regulation of immune response. *Chem Phys Lipids* **108**: 169–190.
- Berdyshev EV, Schmid PC, Dong Z, Schmid HH (2000). Stress-induced generation of N-acyl ethanolamines in mouse epidermal JB6 P⁺ cells. *Biochem J* **346**: 369–374.
- Bergen DC, Silberberg D (2002). Nervous system disorders: a global epidemic. *Arch Neurol* **59**: 1194–1196.
- Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC *et al.* (2000). Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB₂ receptor. *Eur J Pharmacol* **396**: 141–149.
- Condie R, Herring A, Koh WS, Lee M, Kaminski NE (1996). Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2. *J Biol Chem* **271**: 13175–13183.
- Croxford JL, Miller SD (2003). Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R(+)-WIN55,212. *J Clin Invest* **111**: 1231–1240.
- Devane WA, Hanuš L, Breuer A, Pertwee RG, Stevenson LA, Griffin G *et al.* (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science* **258**: 1946–1949.
- Dittel BN, Merchant RM, Janeway Jr CA (1999). Evidence for Fas-dependent and Fas-independent mechanisms in the pathogenesis of experimental autoimmune encephalomyelitis. *J Immunol* **162**: 6392–6400.
- Galiègue S, Mary S, Marchand J, Dussosoy D, Carrière D, Carayon P *et al.* (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. *Eur J Biochem* **232**: 54–61.
- Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, Wiley JL *et al.* (1999). 3-(1',1'-Dimethylbutyl)-1-deoxy-Δ⁸-THC and related

- compounds: synthesis of selective ligands for the CB₂ receptor. *Bioorg Med Chem* 7: 2905–2914.
- Huseby ES, Liggitt D, Brabb T, Schnabel B, Öhlen C, Goverman J (2001). A pathogenic role for myelin-specific CD8⁺ T cells in a model for multiple sclerosis. *J Exp Med* 194: 669–676.
- Ji Q, Goverman J (2007). Experimental autoimmune encephalomyelitis mediated by CD8⁺ T cells. *Ann N Y Acad Sci* 1103: 157–166.
- Johnson AJ, Suidan GL, McDole J, Pirko I (2007). The CD8T cell in multiple sclerosis: suppressor cell or mediator of neuropathology? *Int Rev Neurobiol* 79: 73–97.
- Kaminski NE, Abood ME, Kessler FK, Martin BR, Schatz AR (1992). Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. *Mol Pharmacol* 42: 736–742.
- Killestein J, Uitdehaag BM, Polman CH (2004). Cannabinoids in multiple sclerosis: do they have a therapeutic role? *Drugs* 64: 1–11.
- Klein TW (2005). Cannabinoid-based drugs as anti-inflammatory therapeutics. *Nat Rev Immunol* 5: 400–411.
- Klein TW, Kawakami Y, Newton C, Friedman H (1991). Marijuana components suppress induction and cytolytic function of murine cytotoxic T cells *in vitro* and *in vivo*. *J Toxicol Environ Health* 32: 465–477.
- Klein TW, Newton C, Larsen K, Chou J, Perkins I, Lu L *et al.* (2004). Cannabinoid receptors and T helper cells. *J Neuroimmunol* 147: 91–94.
- Lee SF, Newton C, Widen R, Friedman H, Klein TW (2001). Differential expression of cannabinoid CB₂ receptor mRNA in mouse immune cell subpopulations and following B cell stimulation. *Eur J Pharmacol* 423: 235–241.
- Lyman WD, Sonett JR, Brosnan CF, Elkin R, Bornstein MB (1989). Δ⁹-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. *J Neuroimmunol* 23: 73–81.
- Marez K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN (2005). Modulation of the cannabinoid CB₂ receptor in microglial cells in response to inflammatory stimuli. *J Neurochem* 95: 437–445.
- Marez K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP *et al.* (2007). Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB₁ on neurons and CB₂ on autoreactive T cells. *Nat Med* 13: 492–497.
- Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. *Nature* 346: 561–564.
- Mechoulam R, Ben-Shabat S, Hanuš L, Ligumsky M, Kaminski NE, Schatz AR *et al.* (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. *Biochem Pharmacol* 50: 83–90.
- Mestre L, Correa F, Arévalo-Martín A, Molina-Holgado E, Valenti M, Ortat G *et al.* (2005). Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. *J Neurochem* 92: 1327–1339.
- Morahan PS, Klykken PC, Smith SH, Harris LS, Munson AE (1979). Effects of cannabinoids on host resistance to *Listeria monocytogenes* and herpes simplex virus. *Infect Immun* 23: 670–674.
- Munoz JJ, Bernard CC, Mackay IR (1984). Elicitation of experimental allergic encephalomyelitis (EAE) in mice with the aid of pertussigen. *Cell Immunol* 83: 92–100.
- Munro S, Thomas KL, Abu-Shaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. *Nature* 365: 61–65.
- Ni X, Geller EB, Eppihimer MJ, Eisenstein TK, Adler MW, Tuma RF (2004). Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. *Mult Scler* 10: 158–164.
- Ortega-Gutiérrez S, Molina-Holgado E, Arévalo-Martín A, Correa F, Viso A, López-Rodríguez ML *et al.* (2005). Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. *FASEB J* 19: 1338–1340.
- Patel S, Carrier EJ, Ho WS, Rademacher DJ, Cunningham S, Reddy DS *et al.* (2005). The postmortal accumulation of brain N-arachidonylethanolamine (anandamide) is dependent upon fatty acid amide hydrolase activity. *J Lipid Res* 46: 342–349.
- Pertwee RG (2002). Cannabinoids and multiple sclerosis. *Pharmacol Ther* 95: 165–174.
- Pryce G, Ahmed Z, Hankey DJ, Jackson SJ, Croxford JL, Pocock JM *et al.* (2003). Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. *Brain* 126: 2191–2202.
- Saario SM, Savinainen JR, Laitinen JT, Järvinen T, Niemi R (2004). Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. *Biochem Pharmacol* 67: 1381–1387.
- Salzet M, Breton C, Bisogno T, Di Marzo V (2000). Comparative biology of the endocannabinoid system. Possible role in the immune response. *Eur J Biochem* 267: 4917–4927.
- Sánchez AJ, González-Pérez P, Galve-Roperh I, García-Merino A (2006). R-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB₂ receptor. *Biochem Pharmacol* 72: 1697–1706.
- Schatz AR, Koh WS, Kaminski NE (1993). Δ⁹-Tetrahydrocannabinol selectively inhibits T-cell dependent humoral immune responses through direct inhibition of accessory T-cell function. *Immunopharmacology* 26: 129–137.
- Schatz AR, Lee M, Condie RB, Pulaski JT, Kaminski NE (1997). Cannabinoid receptors CB₁ and CB₂: a characterization of expression and adenylate cyclase modulation within the immune system. *Toxicol Appl Pharmacol* 142: 278–287.
- Schmid PC, Zuzarte-Augustin ML, Schmid HH (1985). Properties of rat liver N-acylethanolamine amidohydrolase. *J Biol Chem* 260: 14145–14149.
- Shoemaker JL, Joseph BK, Ruckle MB, Mayeux PR, Prather NL (2005). The endocannabinoid noladin ether acts as a full agonist at human CB₂ cannabinoid receptors. *J Pharmacol Exp Ther* 314: 868–875.
- Sospedra M, Martin R (2005). Immunology of multiple sclerosis. *Annu Rev Immunol* 23: 683–747.
- Sugiura T, Kondo S, Kishimoto S, Miyashita T, Nakane S, Kodaka T *et al.* (2000a). Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB₂ receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. *J Biol Chem* 275: 605–612.
- Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K *et al.* (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. *Biochem Biophys Res Commun* 215: 89–97.
- Sugiura T, Oka S, Gokoh M, Kishimoto S, Waku K (2004). New perspectives in the studies on endocannabinoid and cannabis: 2-arachidonoylglycerol as a possible novel mediator of inflammation. *J Pharmacol Sci* 96: 367–375.
- Sugiura T, Waku K (2000). 2-Arachidonoylglycerol and the cannabinoid receptors. *Chem Phys Lipids* 108: 89–106.
- Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K *et al.* (2005). Identification and functional characterization of brainstem cannabinoid CB₂ receptors. *Science* 310: 329–332.
- Walter L, Stella N (2004). Cannabinoids and neuroinflammation. *Br J Pharmacol* 141: 775–785.
- Wirguin I, Mechoulam R, Breuer A, Schezen E, Weidenfeld J, Brenner T (1994). Suppression of experimental autoimmune encephalomyelitis by cannabinoids. *Immunopharmacology* 28: 209–214.
- Yuan M, Kiertscher SM, Cheng Q, Zoumalan R, Tashkin DP, Roth MD (2002). Δ⁹-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. *J Neuroimmunol* 133: 124–131.
- Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A *et al.* (2003). Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. *Lancet* 362: 1517–1526.